TP53 and ovarian cancer: The required concentration of each compound leading to 50% growth inhibition (GI50) showed that wild-type TP53 ovarian cancer cell lines were significantly more sensitive to Nutlin-3/RG7388 compared to mutant, which is consistent with their mechanism of action (p<0.0001 Mann-Whitney test).